Face Recognition

This thesis deals with human recognition on a videorecording. Convolution neural network was used for face recognition, from which we will get multidimensional vector, which will allow to determine person’s identity. There are demands imposed on the system, for it to be able to work in real time and could be used for example for person recognition at various conferences, or as a part of security system. Whole system is written in Python language. Part of this thesis is dataset in form of videorecords with persons

Temporal trends in percentage of individuals successfully clinically retained in the NA-ACCORD by CDC-defined region of the United States, from 2000–2010, by CDC-defined region of the United States.

<p>Diamonds are National HIV/AIDS Strategy/Institute of Medicine retention indicator percentages (≥2 visits in a calendar year, >90 days apart). Circles are Predictive Margins for the Probability of Being Retained by IOM indicator using a Region-by-Time interaction effect (Fully Adjusted Logistic Model with GEE) U.S. Centers for Disease Control and Prevention (CDC)-defined Regions: <i>Northeast</i>: CT, ME, MA, NH, NJ, NY, PA, RI, VT; <i>Midwest</i>: IL, IN, IA, KS, MI, MN, MO, NE, ND, OH, SD, WI; <i>South</i>: AL, AR, DE, DC, FL, GA, KY, LA, MD, MS, NC, OK, SC, TN, TX, VA, WV; <i>West</i>: AK, AZ, CA, CO, HI, ID, MT, NV, NM, OR, UT, WA, WY.</p

Life expectancy estimates (LEE) and standard errors (SE) at age 20 years using weighted and unweighted mortality rates, 2000 to 2007.

<p>Note: LEE, <i>life expectancy estimate (years)</i>; SE, <i>standard error</i>; ART, <i>combination antiretroviral therapy</i>.</p><p>In effort to reduce bias from informative censoring, we used weighted regression methods to estimate mortality rates, using an indicator variable that was created to identify participants who were lost to follow-up. Further details are available in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0081355#pone.0081355.s002" target="_blank">Appendix S2</a>.</p

Age-specific unweighted mortality rates (per 1000 person-years), by calendar-period, among individuals on ART in the NA-ACCORD, 2000–2007.

<p>Note: PY, person-years; ART, combination antiretroviral therapy.</p

Life expectancy estimates (LEE) and standard errors (SE) at age 20 years using unweighted mortality rates, by calendar period, 2000 to 2007.

<p>Note: LEE, <i>life expectancy estimate (years)</i>; SE, <i>standard error</i>; ART, <i>combination antiretroviral therapy</i>.</p

Mid-point life expectancy estimates at age 20 years in three calendar periods, overall and by sociodemographic characteristics, 2000–2007.

<p>Panel A: Life expectancy at age 20 years, overall. Panel B: Life expectancy at age 20 years, by sex. Panel C: Life expectancy at age 20 years, by transmission group. Panel D: Life expectancy at age 20 years, by race. Panel E: Life expectancy at age 20 years, by CD4 cell count (cells/mm³) at ART initiation.</p

Flow charts showing selection into each of the two analyses.

<p>Gray indicates the population of interest for the propensity score-matched analyses.</p

Characteristics of newly treatment-eligible HIV-infected U.S. residents in NA-ACCORD, 2001–2009.

<p>ART = antiretroviral therapy, IQR = interquartile range. Percentages may not add up to 100 due to rounding.</p>*<p>See <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0078952#pone-0078952-g001" target="_blank">Figure 1</a> for details of study selection procedure.</p

Map of U.S. states represented in study.

<p>Map of U.S. states represented in study.</p

Population size, deaths, and unweighted mortality rate, overall and by select categories, 2000 to 2007.

<p>Per 1,000 person-years.</p><p>CI: Confidence Interval.</p><p>Note: ART, <i>combination antiretroviral therapy</i>.</p